RelieVRx for Total Knee Arthroplasty (TKA) for the Reduction of Acute Postoperative Pain and Opioid Use
Status:
Recruiting
Trial end date:
2022-02-01
Target enrollment:
Participant gender:
Summary
This is a single-center, prospective, randomized, controlled study of the appliedVR RelieVRx
headset in subjects undergoing Total Knee Arthroplasty (TKA). This study will evaluate two
primary endpoints - effectiveness of a single use of RelieVRx in the reduction of acute
postoperative pain by 20%; and overall effectiveness of RelieVRx as an opioid-sparing
intervention, where opioid consumption is reduced by at least 20% over a 90-day postoperative
period in the interventional, standard of care (SOC) plus RelieVRx group compared to the
control, SOC group.